^
Association details:
Biomarker:HER-2 expression
Cancer:Solid Tumor
Drug:ABL105 (HER2 inhibitor, CD137 agonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

544P - A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation

Published date:
09/13/2021
Excerpt:
YH32367 stimulated IFN-γ secretion and thereby inducing tumor cells lysis in co-culture assay with hPBMC and HER2-expressing tumor cells. YH32367 also showed superior efficacies on immune cells activation as well as tumor growth inhibition in both HER2-expressing tumor-bearing hPBMC humanized mice...It suggests that YH32367 could be promising to develop for the patients with HER2 positive cancer as an effective HER2-directed therapy.